CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026
Harbour BioMed has secured a major legal victory in one of the biotechnology industry’s most closely watched intellectual property disputes, with a U.S. jury ruling in favor of the company in its patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio. The verdict represents a significant milestone for the global antibody therapeutics sector, validating the strength of Harbour BioMed’s proprietary Harbour Mice® antibody discovery platform and reinforcing the importance of protecting innovation in next-generation biologics development. The jury unanimously found that Amgen infringed Harbour BioMed’s patented antibody discovery technology, that the infringement was willful, and that the patent at issue remains valid. The court awarded Harbour BioMed $20.2 million in damages, the full amount requested by the company, with the possibility of the award increasing to $60.6 million if the court grants enhanced damages based on the finding of willful infringement.
Jury Upholds Antibody Discovery Patent and Awards Full Damages
The case was originally filed in 2021 by Harbour Antibodies, a member of the Harbour BioMed group, which alleged that Amgen had infringed intellectual property protecting its groundbreaking antibody discovery platform. The disputed technology was developed by Professor Frank Grosveld, one of the founders of Harbour Antibodies, and has become an important component of modern therapeutic antibody research. Following several years of litigation, the case proceeded to trial in the United States District Court for the District of Delaware in June 2026.
Harbour BioMed successfully argued that Amgen utilized patented innovations without authorization, resulting in a decisive verdict after only three hours of jury deliberation. The jury confirmed infringement, validated the patent’s legal standing, and determined that the infringement was intentional. The decision is considered particularly notable given the complexity of biotechnology patent litigation and the rarity of substantial jury awards in high-profile intellectual property cases within the Delaware court system.
Victory Strengthens Global Antibody Innovation Landscape
Advertisement
The verdict is being viewed as a significant development for the global biopharmaceutical industry, particularly in the field of antibody therapeutics where intellectual property protection plays a critical role in fostering scientific innovation and commercial investment. Harbour BioMed stated that the decision validates years of research and development invested in its proprietary transgenic rodent technology and reinforces confidence in its broader antibody discovery engine. The company has built an extensive portfolio of technologies, including Harbour Mice®, HBICE® bispecific antibody platforms, HCAb PLUS™ multi-specific antibody technologies, and AI-driven antibody discovery capabilities.
These technologies are designed to accelerate the development of innovative therapies targeting cancer, autoimmune diseases, and other serious medical conditions. Industry observers believe the outcome could influence future patent disputes involving antibody discovery technologies and strengthen the legal protections available to biotechnology innovators developing next-generation therapeutic platforms.
Harbour BioMed Targets Broader Patent Enforcement Strategy
Beyond the current victory, Harbour BioMed indicated that it will continue to defend and enforce its broader intellectual property portfolio. The company revealed that another patent within its portfolio may carry significantly greater financial implications, potentially representing damages worth up to ten times the amount awarded in the current case. Management emphasized that protecting scientific innovation remains a core strategic priority as the company continues to expand its research capabilities and therapeutic pipeline.
Harbour BioMed currently focuses on developing novel antibody therapeutics across immunology, oncology, and other disease areas while leveraging artificial intelligence and advanced biologics technologies to improve drug discovery efficiency. The landmark verdict not only strengthens the company’s position within the global biotechnology sector but also sends a powerful message regarding the value of intellectual property protection in advancing medical innovation. As competition intensifies in the rapidly growing antibody therapeutics market, the outcome is expected to have lasting implications for biotechnology companies, investors, and innovators worldwide.
Source: Harbour BioMed press release
